COMMUNIQUÉS West-GlobeNewswire

AB Science announces the publication of a previously unknown mechanism linked to the progression of ALS and that further reinforces the rationale why masitinib might be protective in ALS
08/10/2018
Paris, October 8, 2018, 8.30am Research led by an international academic team reveals a novel pathogenic mechanism for ALS that can be therapeutically targeted by masitinib Results published in the Journal of Clinical [...]
AB Science la publication d'un mécanisme jusque-ici inconnu en lien avec la progression de la sclérose latérale amyotrophique (SLA) et qui corrobore l'effet protecteur du masitinib dans la SLA
08/10/2018
Paris, 8 octobre 2018, 8h30 Des recherches menées par une équipe universitaire internationale révèlent un nouveau mécanisme pathogène de la SLA pouvant être ciblé thérapeutiquement par le masitinib Les résultats publiés [...]
RAMSAY GENERALE DE SANTE : OPA CAPIO
08/10/2018
PRESS RELEASE THIS PRESS RELEASE MAY NOT, DIRECTLY OR INDIRECTLY, BE DISTRIBUTED OR PUBLISHED IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, OR SOUTH AFRICA. THE OFFER IS NOT BEING MADE TO (AND ACCEPTANCES [...]
RAMSAY GENERALE DE SANTE : OPA CAPIO
08/10/2018
COMMUNIQUE DE PRESSE LE PRESENT COMMUNIQUE DE PRESSE NE PEUT ETRE, DIRECTEMENT OU INDIRECTEMENT, DISTRIBUE OU PUBLIE EN AUSTRALIE, CANADA, HONG KONG, JAPON, NOUVELLE ZELANDE, OU AFRIQUE DU SUD. L'OFFRE N'EST PAS FAITE [...]
Akers Biosciences Announces a Leadership Change, Strategic Update, Legal Settlement and an AIM Update
08/10/2018
THOROFARE, N.J., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, announces a leadership change [...]
Rule 2.9 Announcement
08/10/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 8 October 2018 [...]
Surrender of Share Options
08/10/2018
Summit Therapeutics plc (‘Summit’ or the ’Company’) Surrender of Share Options Oxford, UK, and Cambridge, MA, US, 8 October 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic [...]
Frost & Sullivan gives award for best innovation in the cosmetics sector to Bio-on
08/10/2018
Minerv Bio Cosmetics, the 100% natural bioplastic microspheres biodegradable in soil and water, are named the year’s most innovative biobased product in the cosmetics sector. Frost & Sullivan finds that “Bio-On is [...]
Frost & Sullivan décerne à Bio-on un prix pour la meilleure des innovations dans le secteur des produits cosmétiques
08/10/2018
Minerv Bio Cosmetics, microsphères de bioplastique, naturelles et entièrement (100%) biodégradables dans l’eau et dans le sol, représentent le produit à base biologique le plus innovant de l’année dans le secteur des [...]
Novartis announces FDA and EMA filing acceptance of siponimod, the first and only drug shown to meaningfully delay disability progression in typical SPMS patients
08/10/2018
There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS) - a highly debilitating form of MS characterized by gradual, irreversible worsening of disability, largely [...]
Health Needs Spike for Survivors of Indonesia’s Earthquake and Tsunami
06/10/2018
Millwood, VA, Oct. 06, 2018 (GLOBE NEWSWIRE) -- Project HOPE says serious health needs are increasing daily as survivors try to come to grips with the aftermath of the devastating earthquake and tsunami in Indonesia [...]
Loxo Oncology Announces LOXO-292 Durability Update in Patients with RET-Mutant Medullary Thyroid Cancer and RET Fusion-Positive Thyroid Cancer from LIBRETTO-001 at the 88th Annual Meeting of the American Thyroid Association
06/10/2018
- 16/17 (94%) Responding RET-Mutant Medullary Thyroid Cancer Patients Remain on Therapy, With Median Follow-Up of 8.4 Months - - 7/7 (100%) Responding RET Fusion-Positive Thyroid Cancer Patients Remain on Therapy, With [...]
New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy
06/10/2018
NURTURE study participants were alive and did not require permanent ventilation, in contrast to natural history of spinal muscular atrophy (SMA) Study participants achieved motor milestones with 100 percent sitting [...]
Akcea et Ionis annoncent l’homologation de TEGSEDIMC (inotersen pour injection) au Canada
06/10/2018
Le premier et le seul traitement de ce type pour les Canadiens atteints d’amylose héréditaire liée à la transthyrétine (hATTR) avec polyneuropathie, une maladie héréditaire rare OTTAWA et BOSTON et CARLSBAD, Californie [...]
Adamas Announces New Employment Inducement Grant
05/10/2018
EMERYVILLE, Calif., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted nine new employees the option [...]
Akcea Announces Its Access and Distribution Strategy for TEGSEDI™ (inotersen)
05/10/2018
Express Scripts’ Accredo® selected as specialty pharmacy for its expertise in providing timely access and support services for patients living with rare diseases BOSTON, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Akcea [...]
Akcea and Ionis Receive FDA Approval of TEGSEDI™ (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
05/10/2018
TEGSEDI provides powerful knockdown of TTR protein, delivering significant and sustained benefits in neuropathy and quality of life TEGSEDI is an effective treatment choice that allows self-administration at a time and [...]
Cogentix Medical, Inc. / Laborie Medical Technologies Canada ULC Merger Litigation
05/10/2018
TORONTO, Oct. 05, 2018 (GLOBE NEWSWIRE) -- On March 11, 2018, Cogentix Medical, Inc. (“Cogentix”) and certain affiliates of Laborie Medical Technologies Canada ULC (“Laborie”), LM US Parent, Inc. (“Parent”) and Camden [...]
Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/10/2018
BURLINGTON, Mass., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced a grant of inducement stock options to three new employees for an aggregate of 20,600 shares of common stock [...]

Pages